Adalimumab (Humira®)
Economic evaluation of Adalimumab (Humira®) in combination with methotrexate for polyarticular juvenile idiopathic arthritis in children and adolescents (4-17yrs) in patients who have had an inadequate response to DMARDs. Also licensed as monotherapy in cases of intolerance to MTX or when continued therapy with MTX is inappropriate.
Rapid Review
Commenced | Completed | Outcome |
20/05/2011 | 02/06/2011 | Full Pharmacoeconomic Evaluation not Recommended |